INTERNATIONAL PATENT: TAIHO PHARMACEUTICAL CO., LTD., MSD INTERNATIONAL GMBH FILES APPLICATION FOR "METHODS OF TREATING CANCER USING FUTIBATINIB, PEMBROLIZUMAB AND AT LEAST ONE ADDITIONAL CHEMOTHERAPEUTIC AGENT"

GENEVA, March 9 -- TAIHO PHARMACEUTICAL CO., LTD. (1-27 KandanishikichoChiyoda-ku, Tokyo 101-8444), MSD INTERNATIONAL GMBH (Weystrasse 206006 Luzern) filed a patent application (PCT/IB2024/058465) for "METHODS OF TREATING CANCER USING FUTIBATINIB, PEMBROLIZUMAB AND AT LEAST ONE ADDITIONAL CHEMOTHERAPEUTIC AGENT" on Aug 30, 2024. With publication no. WO/2025/046537, the details related to the patent application was published on Mar 06, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): HIRAYAMA, Naoki (C/O TAIHO PHARMACEUTICAL CO., LTD.1-27 KandanishikichoChiyoda-ku, Tokyo 101-8444)

Abstract: ...